Navigation Links
High-dose melphalan and autologous stem cell transplantation increases survival
Date:10/26/2011

Boston - A team of researchers led by Boston University School of Medicine (BUSM), has found treatment of selected immunoglobulin light chain (AL) amyloidosis patients with high-dose melphalan and autologous stem cell transplantation (HDM/SCT) resulted in a high organ response rate and increased overall survival (OS), even for those patients who did not achieve a hematologic complete response (CR). These findings appear in the current issue of Blood.

AL amyloidosis is the most common form of systemic amyloidosis, with an incidence of five to 12 persons per million per year. In AL amyloidosis, clonal bone marrow plasma cells produce monoclonal light chains that misfold and deposit in tissues and organs as amyloid fibrils, resulting in progressive system and organ failure and ultimately in death.

Untreated patients with this disease have a dismal outcome, with a median survival of 10-14 months from diagnosis. Moreover, fewer than five percent of patients survived for 10 years before the introduction of HDM/SCT.

The BUSM researchers analyzed a series of 421 patients treated with HDM/SCT and compared outcomes for patients with and without CR. Treatment related mortality was 11.4 percent overall (5.6 percent in the last 5 years). The CR rate was 34 percent and the median event-free survival (EFS) and OS were 2.6 and 6.3 years, respectively.

Eighty-one patients died within the first year after HDM/SCT and were not evaluable for hematologic and organ response. Of 340 evaluable patients, 43 percent achieved CR and 78 percent of them experienced an organ response. For CR patients, median EFS and OS were 8.3 and 13.2 years, respectively. Among the 195 patients who did not obtain CR, 52 percent achieved an organ response, and their median EFS and OS were 2 and 5.9 years, respectively.

"This study provides the longest outcome data on AL patients treated with HDM/SCT, including OS, EFS, and long-term mortality," explained senior author Martha Skinner, MD, former director of BUSM's Amyloid Treatment and Research Program as well as a professor of medicine at BUSM. "Our results demonstrate that, with careful patient selection and experienced management, low rates of treatment related mortality can be achieved.

According to the authors, despite the importance of attaining CR, achievement of partial response often results in a long period of stable or improved diseases. "We pioneered HDM/SCT treatment for AL amyloidosis in 1994. This long term review shows durable hmetologic and organ responses for most patients with an overall survival greatly exceeding what it was prior to HDM/SCT treatment," she added.


'/>"/>
Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. High-Dose Statins May Increase Diabetes Risk
2. Jefferson doctors strengthen case for high-dose radiotherapy technique after radical prostatectomy
3. New model may simplify high-dose radiosurgery planning
4. High-Dose Vitamin B Risky for Diabetics With Kidney Disease
5. Autologous Bone Marrow Stem Cells Transplant into Parkinson's Disease Patients is Safe and May Improve Their Quality of Life
6. Lab-made skin cells will aid transplantation, cancer, drug discovery research
7. Living donor liver transplantation improves survival over deceased donor transplants
8. Cell Transplantation study shows bone growth from implanted tooth and dental pulp stem cells
9. CDC Moves to Make Organ Transplantation Safer
10. Bone marrow transplantation may increase cancer resistance in patients
11. Study finds important risk factors for death/transplantation in children with heart muscle disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, Doctors on ... to help personal injury victims find high quality medical care. When the company started ... area. Fast forward to present day and the now ten-page directory features a vast ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) Portland ... autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being launched ... other caregivers the opportunity to share stories and advice, seek help, and continue their ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... inspirational interview of two ostomy patients, standing as living proof that attitude and ... from digestive diseases and issues that spike around the holidays. This campaign will ...
(Date:12/2/2016)... Delaware (PRWEB) , ... December 02, 2016 , ... ... released a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps ... sample entry through labeling, storing, shipping and disposal. The new version is a ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ... and night. No other wearable health technology on the market can deliver all that ... poeple more meaningful insights about their health than the usual heart rate and steps ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016  The Addiction Treatment Advisory ... of Managed Care Pharmacy (AMCP), has released detailed ... address the opioid addiction crisis, including through improved ... ATAG,s newly released paper, "The Role ... Naloxone," addresses many issues around gaps and barriers ...
(Date:12/2/2016)...  Maxor National Pharmacy Services, LLC ("Maxor"), today announced that ... The combination of Texas -based Maxor Specialty ... bring together both company,s clinical expertise and high-touch patient service ... specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... -- CVS Health Corporation (NYSE: CVS ) ... December 15, 2016, beginning at 8:00 a.m. (ET). Senior members ... in-depth review of the company,s strategies to drive long-term ... discuss 2017 earnings guidance during the event. ... be broadcast simultaneously on the Investor Relations portion of ...
Breaking Medicine Technology: